How can I find financial assistance for patients with Revlimid?
BMS Access Support ® can help identify financial assistance programs for eligible patients who have been prescribed REVLIMID and who need help managing the cost of treatment. The appropriate program will depend on the patient’s coverage.
Where can I find more information about Celgene REMS programs?
If you would like to obtain more information about any of the Celgene-administered REMS programs, please click on the program name below: www.LenalidomideREMS.com, to learn more about the Lenalidomide REMS program. www.POMALYSTREMS.com, to learn more about the POMALYST REMS ® program.
Is Revlimid a registered trademark of Celgene?
REVLIMID ®, POMALYST ®, POMALYST REMS ®, IMiD ®, and associated logos are registered trademarks of Celgene Corporation, a Bristol-Myers Squibb Company. Access Support ® and the related logo are registered trademarks of Bristol-Myers Squibb Company. Other trademarks are property of their respective owners. Do not use REVLIMID during pregnancy.
What is Revlimid used to treat?
REVLIMID ® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT).
Is Revlimid considered chemotherapy?
Revlimid | Chemotherapy Drug Information | Chemocare.com.
How long can you take Revlimid?
You won't take the drug on days 22 to 28. Revlimid can be taken for up to 12 cycles. Your doctor will likely prescribe Revlimid with the medication rituximab (Truxima, Rituxan).
What is the monthly cost of Revlimid?
Celgene launched Revlimid in 2005 at a price of $215 per pill. After more than 20 price hikes, the drug now costs $763 per pill, or $16,023 per month.
What tier drug is Revlimid?
What drug tier is Revlimid typically on? Medicare prescription drug plans typically list Revlimid on Tier 5 of their formulary. Generally, the higher the tier, the more you have to pay for the medication.
What is the success rate of REVLIMID?
Patients who took REVLIMID and dexamethasone continuously had a 75% response rate compared to 73% of patients who took REVLIMID and dexamethasone for only 18 months and 62% of patients who took the combination of melphalan, prednisone, and thalidomide.
What are the long term effects of taking REVLIMID?
It's possible that Revlimid can cause long-term side effects. For example, this medication may cause: liver problems, such as liver failure. other types of cancer, such as skin cancer or leukemia.
What is the life expectancy for multiple myeloma Stage 3?
Multiple myeloma is cancer that affects bone marrow and a type of blood cell known as plasma cells. The cancer damages bones and prevents the body from making healthy blood cells. People do not often experience multiple myeloma symptoms until they reach stage 3....Life expectancy.StageMedian survival162 months244 months329 monthsFeb 27, 2018
Is there a generic available for Revlimid?
Generic Versions of Revlimid and Velcade Now Available for Patients With Multiple Myeloma. In the first half of 2022, the Food and Drug Administration (FDA) approved generic versions of the two drugs most commonly used as the backbone of multiple myeloma combination therapies, Revlimid and Velcade.
What time of day should I take Revlimid?
REVLIMID is an oral medication taken once daily at about the same time each day, with or without food: You can take REVLIMID at home or wherever you choose. The recommended starting dose of REVLIMID is 25 mg/day for 21 days of a 28-day cycle; your doctor will tell you which dose is right for you.
What is the cost of Revlimid in Canada?
In Canada, Revlimid costs between $8,000 and $10,000 Canadian per month, depending on dosage.
Is GoodRx better than Part D?
GoodRx can also help you save on over-the-counter medications and vaccines. GoodRx prices are lower than your Medicare copay. In some cases — but not all — GoodRx may offer a cheaper price than what you'd pay under Medicare. You won't reach your annual deductible.
Does Medicare cover multiple myeloma treatments?
"As most patients with myeloma in the United States are covered by Medicare, our results have important implications both for the clinicians who care for these patients and for health-care policy that tackles coverage of oral and parenteral anticancer therapy."
How long does treatment last for multiple myeloma?
Myeloma is not usually curable but treatment can control it. You usually have treatment for four to six months. Then if you are fit enough, your specialist might suggest intensive treatment using high dose chemotherapy with a stem cell transplant.
How Long Can multiple myeloma stay in remission?
The period of time between relapses varies from person to person. But for many, the first remission can last 2 years or more.
How long do patients live with multiple myeloma?
The median length of survival after diagnosis with multiple myeloma is 62 months for Stage I, 44 months for Stage II, and 29 months for Stage III. Life expectancy depends on many factors, including the person's age, health, kidney function, and more.
Can revlimid cause liver damage?
The evidence suggests that lenalidomide may be associated with drug-induced liver injury. The most compelling evidence of a causal association derives from the results of liver biopsies, and cases in which there has been a positive dechallenge or a positive rechallenge.
How BMS Access Support May Help
Find out how BMS can work with patients and their healthcare providers to help access a prescribed BMS medication.
Financial Support Options
There may be programs and services that could help with the cost of treatment. Learn about what options are available.
Additional Resources
We provide videos, tools, and other resources that may help with your access and reimbursement needs.
Patients With Commercial (Private) Insurance
The BMS Oncology Co-Pay Assistance Program helps commercially insured patients who have been prescribed select BMS medications with out-of-pocket deductibles, co-pays, or co-insurance requirements. Eligible patients may pay as little as $10 per one-month supply, up to a maximum of $15,000 per calendar year.
Patients With Insurance Through Federal Healthcare Programs
Patients insured through Federal Healthcare Programs are not eligible for co-pay assistance programs sponsored by Bristol Myers Squibb.
Patients Without Prescription Drug Coverage or Who Are Underinsured
For patients without prescription drug insurance or for patients who are underinsured, BMS Access Support can make a referral to independent charitable foundations that may be able to help.
What is Celgene patient support?
Celgene Patient Support® is here to help you and your loved ones understand the financial help that may be available for REVLIMID®.
How to contact Celgene insurance?
Call your Specialist at 1-800-931-8691. If you have commercial insurance, you may qualify for the Celgene Commercial Co-pay Program. If you qualify, your out-of-pocket co-pay responsibility will be $25(subject to annual benefit limit) for REVLIMID.
Is Revlimid a trademark?
Celgene Patient Support®and REVLIMID are registered trademarks of Celgene Corporation. Other trademarks are the property of their respective owners. © 2019 Celgene Corporation 09/19 US-REV-19-0425
Financial assistance
Depending on your patient’s insurance situation, there are programs and organizations that may help pay for REVLIMID.
Insurance-related assistance
Our Specialists are available to assist with each of the following steps in the insurance approval process for REVLIMID. §
Contraindications
Warnings and Precautions
- Embryo-Fetal Toxicity: See Boxed WARNINGS. 1. Females of Reproductive Potential: See Boxed WARNINGS. 2. Males: Lenalidomide is present in the semen of patients receiving the drug. Males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking REVLIMID and for up to 4 weeks after discontinuing REVLIMI…
Multiple Myeloma
- In newly diagnosed: The most frequently reported Grade 3 or 4 reactions included neutropenia, anemia, thrombocytopenia, pneumonia, asthenia, fatigue, back pain, hypokalemia, rash, cataract, lymphop...
- The most common adverse reactions reported in ≥20% (Arm Rd Continuous): diarrhea (45%), anemia (44%), neutropenia (35%), fatigue (33%), back pain (32%), asthenia (28%), insomnia (2…
- In newly diagnosed: The most frequently reported Grade 3 or 4 reactions included neutropenia, anemia, thrombocytopenia, pneumonia, asthenia, fatigue, back pain, hypokalemia, rash, cataract, lymphop...
- The most common adverse reactions reported in ≥20% (Arm Rd Continuous): diarrhea (45%), anemia (44%), neutropenia (35%), fatigue (33%), back pain (32%), asthenia (28%), insomnia (28%), rash (26%),...
- Maintenance Therapy Post Auto-HSCT:The most frequently reported Grade 3 or 4 reactions in ≥20% (REVLIMID arm) included neutropenia, thrombocytopenia, and leukopenia. The serious adverse reactions o...
- The most frequently reported adverse reactions in ≥20% (REVLIMID arm) across both mainte…
Drug Interactions
- Periodically monitor digoxin plasma levels due to increased Cmaxand AUC with concomitant REVLIMID therapy. Patients taking concomitant therapies such as ESAs or estrogen-containing therapies may have an increased risk of thrombosis. It is not known whether there is an interaction between dexamethasone and warfarin. Close monitoring of PT and INR is recommen…
Use in Specific Populations
- PREGNANCY: See Boxed WARNINGS:If pregnancy does occur during treatment, immediately discontinue the drug and refer patient to an obstetrician/gynecologist experienced in reproductive toxicity for f...
- LACTATION: There is no information regarding the presence of lenalidomide in human milk, the effects of REVLIMID on the breastfed infant, or the effects of REVLIMID on milk productio…
- PREGNANCY: See Boxed WARNINGS:If pregnancy does occur during treatment, immediately discontinue the drug and refer patient to an obstetrician/gynecologist experienced in reproductive toxicity for f...
- LACTATION: There is no information regarding the presence of lenalidomide in human milk, the effects of REVLIMID on the breastfed infant, or the effects of REVLIMID on milk production. Because many...
- RENAL IMPAIRMENT: Adjust the starting dose of REVLIMID based on creatinine clearance value and for patients on dialysis.